These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 20159827)
21. Nucleophosmin (NPM) gene rearrangements in Ki-1-positive lymphomas. Bullrich F; Morris SW; Hummel M; Pileri S; Stein H; Croce CM Cancer Res; 1994 Jun; 54(11):2873-7. PubMed ID: 8187071 [TBL] [Abstract][Full Text] [Related]
22. Differential expression of cyclin D3 in ALK+ and ALK- anaplastic large cell lymphoma. Dalton RR; Rassidakis GZ; Atwell C; Wang S; Oyarzo MP; Medeiros LJ Hum Pathol; 2005 Jul; 36(7):806-11. PubMed ID: 16084951 [TBL] [Abstract][Full Text] [Related]
23. Quantitative PCR detection of NPM/ALK fusion gene and CD30 gene expression in patients with anaplastic large cell lymphoma--residual disease monitoring and a correlation with the disease status. Kalinova M; Krskova L; Brizova H; Kabickova E; Kepak T; Kodet R Leuk Res; 2008 Jan; 32(1):25-32. PubMed ID: 17320171 [TBL] [Abstract][Full Text] [Related]
25. Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy. Li R; Morris SW Med Res Rev; 2008 May; 28(3):372-412. PubMed ID: 17694547 [TBL] [Abstract][Full Text] [Related]
27. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Morris SW; Kirstein MN; Valentine MB; Dittmer KG; Shapiro DN; Saltman DL; Look AT Science; 1994 Mar; 263(5151):1281-4. PubMed ID: 8122112 [TBL] [Abstract][Full Text] [Related]
28. STAT5A is epigenetically silenced by the tyrosine kinase NPM1-ALK and acts as a tumor suppressor by reciprocally inhibiting NPM1-ALK expression. Zhang Q; Wang HY; Liu X; Wasik MA Nat Med; 2007 Nov; 13(11):1341-8. PubMed ID: 17922009 [TBL] [Abstract][Full Text] [Related]
29. The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination. Chiarle R; Martinengo C; Mastini C; Ambrogio C; D'Escamard V; Forni G; Inghirami G Nat Med; 2008 Jun; 14(6):676-80. PubMed ID: 18469826 [TBL] [Abstract][Full Text] [Related]
30. miR-135b mediates NPM-ALK-driven oncogenicity and renders IL-17-producing immunophenotype to anaplastic large cell lymphoma. Matsuyama H; Suzuki HI; Nishimori H; Noguchi M; Yao T; Komatsu N; Mano H; Sugimoto K; Miyazono K Blood; 2011 Dec; 118(26):6881-92. PubMed ID: 22042699 [TBL] [Abstract][Full Text] [Related]
31. In vivo T-cell immune response against anaplastic lymphoma kinase in patients with anaplastic large cell lymphomas. Passoni L; Gallo B; Biganzoli E; Stefanoni R; Massimino M; Di Nicola M; Gianni AM; Gambacorti-Passerini C Haematologica; 2006 Jan; 91(1):48-55. PubMed ID: 16434370 [TBL] [Abstract][Full Text] [Related]
32. Beyond NPM-anaplastic lymphoma kinase driven lymphomagenesis: alternative drivers in anaplastic large cell lymphoma. Tabbò F; Ponzoni M; Rabadan R; Bertoni F; Inghirami G; Curr Opin Hematol; 2013 Jul; 20(4):374-81. PubMed ID: 23673339 [TBL] [Abstract][Full Text] [Related]